EUVIMEDEUVIMED entdecken
Open Access

Neurodevelopmental outcomes in children prenatally exposed to opioid maintenance treatment: A population‐based study

Mennatullah Hasan iD, Kimford J Meador iD, Todd N Brothers iD, Shuang Wang, Adam K Lewkowitz iD, Kristina E Ward iD, Jonathan L Slaughter iD, Yichi Zhang, Xuerong Wen iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024

DOI: 10.1002/phar.4616 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Verfasst von Mennatullah Hasan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA. Hauptthemen laut MEDLINE: Opiate Substitution Treatment, Prenatal Exposure Delayed Effects, Buprenorphine, Opioid-Related Disorders. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NHLBI NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Opioid maintenance treatment (OMT), with methadone or buprenorphine, is a key approach for managing opioid use disorder (OUD) during pregnancy. Despite buprenorphine's superior short‐term outcomes, its long‐term effects remain understudied. This study aims to evaluate the effects of prenatal OMT exposure on the incidence of childhood neurodevelopmental disorders (NDDs) considering timing effect.

Methods

A retrospective cohort study using Rhode Island Medicaid data linked to vital statistics from 2008 to 2018 was conducted. The study included pregnancies having live birth from 2008 to 2016 with continuous Medicaid insurance and OUD diagnosis within 3 months preceding conception until delivery. At least one buprenorphine dispensing or a claim of methadone was required for exposure definition. Exposure was evaluated during early (0–90 days) or late (>90 days) gestation, or at any pregnancy phase. NDDs, including autism, attention‐deficit/hyperactivity disorder (ADHD), learning disabilities, speech/language disorders, developmental coordination disorder, intellectual disability, and behavioral disorders, were identified using validated algorithms. Applying Cox proportional‐hazard models with propensity score overlap weighting, adjusted hazard ratios (aHR) were calculated, mitigating potential confounders. Children were followed up from birth until NDD diagnosis, disenrollment, or study end.

Results

Of 416 mother–child dyads with OUD, 40% used methadone and 20% had buprenorphine exposure during pregnancy. NDDs were observed in 36% of children with early methadone exposure compared to 17% in the early buprenorphine exposed group (aHR: 2.75; 95% confidence interval [CI]: 1.42–5.35). Further comparison to late buprenorphine exposure, late methadone exposure was associated with higher NDD risk (aHR: 2.05; 95% CI: 1.09–3.86). Compared to unexposed group, children exposed to methadone during early and late periods showed higher NDD incidences (aHR: 2.33; 95% CI: 1.51–3.60 and aHR: 2.42; 95% CI: 1.54–3.80, respectively).

Discussion

The study suggests that buprenorphine is a good treatment option for OUD during pregnancy due to minimal long‐term neurodevelopmental impacts on children. However, further extensive research is necessary to rule‐out potential confounding.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opiate Substitution TreatmentPrenatal Exposure Delayed EffectsBuprenorphineOpioid-Related DisordersNeurodevelopmental DisordersMethadoneHumansFemalePregnancyRetrospective StudiesChild, PreschoolChildMaleAdultCohort StudiesMedicaidInfantRhode IslandUnited StatesAnalgesics, OpioidInfant, NewbornPregnancy ComplicationsYoung AdultAdolescent

Stichwörter der Autor:innen

buprenorphinemethadoneneurodevelopmental outcomesopioid maintenance treatment

Substanzen

BuprenorphineMethadoneAnalgesics, Opioid

Autor:innen und Institutionen

  • Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA.
  • Department of Neurology, Stanford University, California, USA.
  • Maternal Fetal Medicine, Women and Infants Hospital of Rhode Island, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
  • Nationwide Children's Hospital and The Ohio State College of Medicine, Columbus, Ohio, USA.
  • Department of Computer Science and Statistics, University of Rhode Island, Kingston, Rhode Island, USA.

ORCID-Profile: Mennatullah Hasan, Kimford J Meador, Todd N Brothers, Adam K Lewkowitz, Kristina E Ward, Jonathan L Slaughter, Xuerong Wen

Förderung

  • NICHD NIH HHS
  • NHLBI NIH HHS
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Hasan, M., Meador, K. J., Brothers, T. N., Wang, S., Lewkowitz, A. K., Ward, K. E., Slaughter, J. L., Zhang, Y., & Wen, X. (2024). Neurodevelopmental outcomes in children prenatally exposed to opioid maintenance treatment: A population‐based study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.4616

Vancouver

Hasan M, Meador KJ, Brothers TN, Wang S, Lewkowitz AK, Ward KE, et al. Neurodevelopmental outcomes in children prenatally exposed to opioid maintenance treatment: A population‐based study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.4616

BibTeX
@article{Hasan2024,
  author = {Hasan, Mennatullah and Meador, Kimford J and Brothers, Todd N and Wang, Shuang and Lewkowitz, Adam K and Ward, Kristina E and Slaughter, Jonathan L and Zhang, Yichi and Wen, Xuerong},
  title = {Neurodevelopmental outcomes in children prenatally exposed to opioid maintenance treatment: A population‐based study},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2024},
  doi = {10.1002/phar.4616}
}
Kostenlos starten →